1. The subject of this order is the successive delivery of medicines for the Oncology Center - Maria Skłodowska-Curie Institute in Gliwice.

2. Description of the subject of the contract and the conditions of the contract are included in the forms:

a) assortment and price specification - Annexes 2.1 to 2.9 to the Terms of Reference;

b) model contract - Annex 4 to the ToR.

3. If the medicine in the international name is on the reimbursement list, then the medicine offered must appear on it and its price must be equal to or lower than the funding limits.

4. The Awarding Entity does not envisage concluding a framework agreement, establishing a dynamic purchasing system, electronic auction and supplementary orders.

5. Detailed information on these proceedings is contained in the ToR.

1. Description of the subject of the contract and the conditions of the contract are included in the forms:

a) assortment and price specification - Annexes 2.1 to the ToR;

b) model contract - Annex 4 to the ToR.

2. The drugs subject to this contract have established quality standards.

These standards were established for each drug during its registration and are the same for the chemical substances they contain. Drugs for their use do not require any distinctive elements within individual substances. In addition, every drug that is traded in Poland must be registered.

3. Drugs that are the subject of the contract must be approved for use in Poland in accordance with the provisions of the Pharmaceutical Law of 6.9.2001 (i.e. Journal of Laws of 2019, item 499, as amended) - the contractor should have all documents required by law for marketing in the Republic of Poland for the offered medicine and present them at the request of the customer.

4. The Employer allows the possibility of changing the form of oral forms with the exception of soluble forms and the possibility of changing the ampoule into a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from 1 manufacturer, so that in practice it is possible to combine doses.

6. In tasks in which the dose size has not been provided, the contracting authority reserves the right to place orders for all doses produced by a given manufacturer.

7. If the medicine in the international name is on the reimbursement list, then the medicine offered must be on it and its price must be equal to or lower than the funding limits.

8. The medicinal products on offer must have a validity period of at least 12 months from the date of delivery. The contracting authority allows the possibility of delivery of the subject of the contract with a shelf life less than 12 months only if the contractor obtains the written consent of the contracting authority.

9. Deadline for the performance of the subject of the contract: successively until 31.12.2020, counting from the date of conclusion of the contract or until the financial limit of the contracting authority for the performance of this contract specified in § 3 para. 1 of the agreement constituting an attachment to the ToR.

1. Description of the subject of the contract and the conditions of the contract are included in the forms:

a) Assortment and price specification - Annexes 2.2 to the ToR

b) Contract template - Annex 4 to the ToR

2. The drugs subject to this contract have established quality standards.

These standards were established for each drug during its registration and are the same for the chemical substances they contain. Drugs for their use do not require any distinctive elements within individual substances. In addition, every drug that is traded in Poland must be registered.

3. Drugs that are the subject of the contract must be approved for use in Poland in accordance with the provisions of the Pharmaceutical Law of September 6, 2001 (i.e. Journal of Laws of 2019, item 499 as amended) - the contractor should have all documents required by law for marketing in the Republic of Poland for the offered medicine and present them at the request of the Employer.

4. The Employer allows the possibility of changing the form of oral forms with the exception of soluble forms and the possibility of changing the ampoule into a vial.

5. Preparations with the same chemical name, but with different dosages, must be offered from one manufacturer in order for the doses to be combined in practice.

6. In tasks in which the dose size has not been provided, the contracting authority reserves the right to place orders for all doses produced by a given manufacturer.

7. If the medicine in the international name is on the reimbursement list, then the medicine offered must be on it and its price must be equal to or lower than the funding limits.

8. The medicinal products offered must have a validity period of at least 12 months from the date of delivery. The Employer allows the possibility of delivery of the subject of the contract with a shelf life of less than 12 months only if the Contractor obtains the written consent of the Employer.

9. Deadline for the performance of the subject of the contract: successively until 31.12.2020 from the date of the contract or until the financial limit of the Employer for the performance of this contract specified in § 3 para. 1 of the agreement constituting an attachment to the ToR

1. Description of the subject of the contract and the conditions of the contract are included in the forms:

a) Assortment and price specification - Annexes 2.3 to the ToR

b) Contract template - Annex 4 to the ToR

2. The drugs subject to this contract have established quality standards.

These standards were established for each drug during its registration and are the same for the chemical substances they contain. Drugs for their use do not require any distinctive elements within individual substances. In addition, every drug that is traded in Poland must be registered.

3. Drugs that are the subject of the contract must be approved for use in Poland in accordance with the provisions of the Pharmaceutical Law of September 6, 2001 (i.e. Journal of Laws of 2019, item 499 as amended) - the contractor should have all documents required by law for marketing in the Republic of Poland for the offered medicine and present them at the request of the Employer.

4. The Employer allows the possibility of changing the form of oral forms with the exception of soluble forms and the possibility of changing the ampoule into a vial.

5. Preparations with the same chemical name, but with different dosages, must be offered from one manufacturer in order for the doses to be combined in practice.

6. In tasks in which the dose size has not been provided, the contracting authority reserves the right to place orders for all doses produced by a given manufacturer.

7. If the medicine in the international name is on the reimbursement list, then the medicine offered must be on it and its price must be equal to or lower than the funding limits.

8. The medicinal products offered must have a validity period of at least 12 months from the date of delivery. The Employer allows the possibility of delivery of the subject of the contract with a shelf life of less than 12 months only if the Contractor obtains the written consent of the Employer.

9. Deadline for the performance of the subject of the contract: successively until 31.12.2020 from the date of the contract or until the financial limit of the Employer for the performance of this contract specified in § 3 para. 1 of the agreement constituting an attachment to the ToR

1. Description of the subject of the contract and the conditions of the contract are included in the forms:

a) Assortment and price specification - Annexes 2.4 to the ToR

b) Contract template - Annex 4 to the ToR

2. The drugs subject to this contract have established quality standards.

These standards were established for each drug during its registration and are the same for the chemical substances they contain. Drugs for their use do not require any distinctive elements within individual substances. In addition, every drug that is traded in Poland must be registered.

3. Drugs that are the subject of the contract must be approved for use in Poland in accordance with the provisions of the Pharmaceutical Law of September 6, 2001 (i.e. Journal of Laws of 2019, item 499 as amended) - the contractor should have all documents required by law for marketing in the Republic of Poland for the offered medicine and present them at the request of the Employer.

4. The Employer allows the possibility of changing the form of oral forms with the exception of soluble forms and the possibility of changing the ampoule into a vial.

5. Preparations with the same chemical name, but with different dosages, must be offered from one manufacturer in order for the doses to be combined in practice.

6. In tasks in which the dose size has not been provided, the contracting authority reserves the right to place orders for all doses produced by a given manufacturer.

7. If the medicine in the international name is on the reimbursement list, then the medicine offered must be on it and its price must be equal to or lower than the funding limits.

8. The medicinal products offered must have a validity period of at least 12 months from the date of delivery. The Employer allows the possibility of delivery of the subject of the contract with a shelf life of less than 12 months only if the Contractor obtains the written consent of the Employer.

9. Deadline for the performance of the subject of the contract: successively until 31.12.2020 from the date of the contract or until the financial limit of the Employer for the performance of this contract specified in § 3 para. 1 of the agreement constituting an attachment to the ToR

1. Description of the subject of the contract and the conditions of the contract are included in the forms:

a) Assortment and price specification - Annexes 2.5 to the ToR

b) Contract template - Annex 4 to the ToR

2. The drugs subject to this contract have established quality standards.

These standards were established for each drug during its registration and are the same for the chemical substances they contain. Drugs for their use do not require any distinctive elements within individual substances. In addition, every drug that is traded in Poland must be registered.

3. Drugs that are the subject of the contract must be approved for use in Poland in accordance with the provisions of the Pharmaceutical Law of September 6, 2001 (i.e. Journal of Laws of 2019, item 499 as amended) - the contractor should have all documents required by law for marketing in the Republic of Poland for the offered medicine and present them at the request of the Employer.

4. The Employer allows the possibility of changing the form of oral forms with the exception of soluble forms and the possibility of changing the ampoule into a vial.

5. Preparations with the same chemical name, but with different dosages, must be offered from one manufacturer in order for the doses to be combined in practice.

6. In tasks in which the dose size has not been provided, the contracting authority reserves the right to place orders for all doses produced by a given manufacturer.

7. If the medicine in the international name is on the reimbursement list, then the medicine offered must be on it and its price must be equal to or lower than the funding limits.

8. The medicinal products offered must have a validity period of at least 12 months from the date of delivery. The Employer allows the possibility of delivery of the subject of the contract with a shelf life of less than 12 months only if the Contractor obtains the written consent of the Employer.

9. Deadline for the performance of the subject of the contract: successively until 31.12.2020 from the date of the contract or until the financial limit of the Employer for the performance of this contract specified in § 3 para. 1 of the agreement constituting an attachment to the ToR

1. Description of the subject of the contract and the conditions of the contract are included in the forms:

a) Assortment and price specification - Annexes 2.6 to the ToR

b) Contract template - Annex 4 to the ToR

2. The drugs subject to this contract have established quality standards.

These standards were established for each drug during its registration and are the same for the chemical substances they contain. Drugs for their use do not require any distinctive elements within individual substances. In addition, every drug that is traded in Poland must be registered.

3. Drugs that are the subject of the contract must be approved for use in Poland in accordance with the provisions of the Pharmaceutical Law of September 6, 2001 (i.e. Journal of Laws of 2019, item 499 as amended) - the contractor should have all documents required by law for marketing in the Republic of Poland for the offered medicine and present them at the request of the Employer.

4. The Employer allows the possibility of changing the form of oral forms with the exception of soluble forms and the possibility of changing the ampoule into a vial.

5. Preparations with the same chemical name, but with different dosages, must be offered from one manufacturer in order for the doses to be combined in practice.

6. In tasks in which the dose size has not been provided, the contracting authority reserves the right to place orders for all doses produced by a given manufacturer.

7. If the medicine in the international name is on the reimbursement list, then the medicine offered must be on it and its price must be equal to or lower than the funding limits.

8. The medicinal products offered must have a validity period of at least 12 months from the date of delivery. The Employer allows the possibility of delivery of the subject of the contract with a shelf life of less than 12 months only if the Contractor obtains the written consent of the Employer.

9. Deadline for the performance of the subject of the contract: successively until 31.12.2020 from the date of the contract or until the financial limit of the Employer for the performance of this contract specified in § 3 para. 1 of the agreement constituting an attachment to the ToR

1. Description of the subject of the contract and the conditions of the contract are included in the forms:

a) Assortment and price specification - Annexes 2.7 to the ToR

b) Contract template - Annex 4 to the ToR

2. The drugs subject to this contract have established quality standards.

These standards were established for each drug during its registration and are the same for the chemical substances they contain. Drugs for their use do not require any distinctive elements within individual substances. In addition, every drug that is traded in Poland must be registered.

3. Drugs that are the subject of the contract must be approved for use in Poland in accordance with the provisions of the Pharmaceutical Law of September 6, 2001 (i.e. Journal of Laws of 2019, item 499 as amended) - the contractor should have all documents required by law for marketing in the Republic of Poland for the offered medicine and present them at the request of the Employer.

4. The Employer allows the possibility of changing the form of oral forms with the exception of soluble forms and the possibility of changing the ampoule into a vial.

5. Preparations with the same chemical name, but with different dosages, must be offered from one manufacturer in order for the doses to be combined in practice.

6. In tasks in which the dose size has not been provided, the contracting authority reserves the right to place orders for all doses produced by a given manufacturer.

7. If the medicine in the international name is on the reimbursement list, then the medicine offered must be on it and its price must be equal to or lower than the funding limits.

8. The medicinal products offered must have a validity period of at least 12 months from the date of delivery. The Employer allows the possibility of delivery of the subject of the contract with a shelf life of less than 12 months only if the Contractor obtains the written consent of the Employer.

9. Deadline for the performance of the subject of the contract: successively until 31.12.2020 from the date of the contract or until the financial limit of the Employer for the performance of this contract specified in § 3 para. 1 of the agreement constituting an attachment to the ToR

1. Description of the subject of the contract and the conditions of the contract are included in the forms:

a) Assortment and price specification - Annexes 2.8 to the ToR

b) Contract template - Annex 4 to the ToR

2. The drugs subject to this contract have established quality standards.

These standards were established for each drug during its registration and are the same for the chemical substances they contain. Drugs for their use do not require any distinctive elements within individual substances. In addition, every drug that is traded in Poland must be registered.

3. Drugs that are the subject of the contract must be approved for use in Poland in accordance with the provisions of the Pharmaceutical Law of September 6, 2001 (i.e. Journal of Laws of 2019, item 499 as amended) - the contractor should have all documents required by law for marketing in the Republic of Poland for the offered medicine and present them at the request of the Employer.

4. The Employer allows the possibility of changing the form of oral forms with the exception of soluble forms and the possibility of changing the ampoule into a vial.

5. Preparations with the same chemical name, but with different dosages, must be offered from one manufacturer in order for the doses to be combined in practice.

6. In tasks in which the dose size has not been provided, the contracting authority reserves the right to place orders for all doses produced by a given manufacturer.

7. If the medicine in the international name is on the reimbursement list, then the medicine offered must be on it and its price must be equal to or lower than the funding limits.

8. The medicinal products offered must have a validity period of at least 12 months from the date of delivery. The Employer allows the possibility of delivery of the subject of the contract with a shelf life of less than 12 months only if the Contractor obtains the written consent of the Employer.

9. Deadline for the performance of the subject of the contract: successively until 31.12.2020 from the date of the contract or until the financial limit of the Employer for the performance of this contract specified in § 3 para. 1 of the agreement constituting an attachment to the ToR

1. Description of the subject of the contract and the conditions of the contract are included in the forms:

a) Assortment and price specification - Annexes 2.9 to the Terms of Reference

b) Contract template - Annex 4 to the ToR

2. The drugs subject to this contract have established quality standards.

These standards were established for each drug during its registration and are the same for the chemical substances they contain. Drugs for their use do not require any distinctive elements within individual substances. In addition, every drug that is traded in Poland must be registered.

3. Drugs that are the subject of the contract must be approved for use in Poland in accordance with the provisions of the Pharmaceutical Law of September 6, 2001 (i.e. Journal of Laws of 2019, item 499 as amended) - the contractor should have all documents required by law for marketing in the Republic of Poland for the offered medicine and present them at the request of the Employer.

4. The Employer allows the possibility of changing the form of oral forms with the exception of soluble forms and the possibility of changing the ampoule into a vial.

5. Preparations with the same chemical name, but with different dosages, must be offered from one manufacturer in order for the doses to be combined in practice.

6. In tasks in which the dose size has not been provided, the contracting authority reserves the right to place orders for all doses produced by a given manufacturer.

7. If the medicine in the international name is on the reimbursement list, then the medicine offered must be on it and its price must be equal to or lower than the funding limits.

8. The medicinal products offered must have a validity period of at least 12 months from the date of delivery. The Employer allows the possibility of delivery of the subject of the contract with a shelf life of less than 12 months only if the Contractor obtains the written consent of the Employer.

9. Deadline for the performance of the subject of the contract: successively until 31.12.2020 from the date of the contract or until the financial limit of the Employer for the performance of this contract specified in § 3 para. 1 of the agreement constituting an attachment to the ToR